{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:49:09Z","timestamp":1777625349920,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.xphs.2024.09.016","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T12:01:17Z","timestamp":1727179277000},"page":"3384-3392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oral viscous budesonide solution for enhanced localized treatment of eosinophilic esophagitis through improved mucoadhesion and permeation"],"prefix":"10.1016","volume":"113","author":[{"given":"Dongyu","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiantian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhen","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuyu","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.xphs.2024.09.016_bib0001","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.3748\/wjg.v26.i36.5395","article-title":"Treatment of eosinophlic esophagitis with swallowed topical corticosteroids","volume":"26","author":"Nennstiel","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.xphs.2024.09.016_bib0002","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ajg.2013.71","article-title":"ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE)","volume":"108","author":"Dellon","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"17","key":"10.1016\/j.xphs.2024.09.016_bib0003","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1056\/NEJMra1502863","article-title":"Eosinophilic esophagitis","volume":"373","author":"Furuta","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.016_bib0004","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.gastro.2017.06.067","article-title":"Epidemiology and natural history of eosinophilic esophagitis","volume":"154","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.016_bib0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.xphs.2024.09.016_bib0006","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-pathol-012615-044241","article-title":"Mechanisms of disease of eosinophilic esophagitis","volume":"11","author":"Davis","year":"2016","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.016_bib0007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11882-015-0592-3","article-title":"The immunologic mechanisms of eosinophilic esophagitis","volume":"16","author":"Hill","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.016_bib0008","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1053\/j.gastro.2009.07.007","article-title":"Biology and treatment of eosinophilic esophagitis","volume":"137","author":"Rothenberg","year":"2009","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.xphs.2024.09.016_bib0009","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1007\/s10620-014-3512-9","article-title":"Prevalence of esophageal eosinophilia and eosinophilic esophagitis in adults: a population-based endoscopic study in Shanghai, China","volume":"60","author":"Ma","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.016_bib0010","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaci.2004.11.006","article-title":"Eosinophilic esophagitis: escalating epidemiology?","volume":"115","author":"Straumann","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.xphs.2024.09.016_bib0011","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/j.gastro.2003.09.024","article-title":"Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years","volume":"125","author":"Straumann","year":"2003","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.xphs.2024.09.016_bib0012","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/17474124.2020.1785869","article-title":"Recent insights on the use of topical steroids in eosinophilic esophagitis","volume":"14","author":"Reddy","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.016_bib0013","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cgh.2021.04.022","article-title":"Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial","volume":"20","author":"Hirano","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.016_bib0014","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.gastro.2012.04.049","article-title":"Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis","volume":"143","author":"Dellon","year":"2012","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.xphs.2024.09.016_bib0015","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2010.07.048","article-title":"Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis","volume":"139","author":"Straumann","year":"2010","journal-title":"Gastroenterology"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2024.09.016_bib0016","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000357089","article-title":"Eosinophilic esophagitis - treatment of eosinophilic esophagitis with drugs: corticosteroids","volume":"32","author":"von Arnim","year":"2014","journal-title":"Dig Dis"},{"key":"10.1016\/j.xphs.2024.09.016_bib0017","series-title":"CADTH Canadian Drug Expert Committee Recommendation: Budesonide (Jorveza\u2014Avir Pharma Inc.): Indication: Eosinophilic Esophagitis","year":"2020"},{"key":"10.1016\/j.xphs.2024.09.016_bib0018","series-title":"Clinical Review Report: Budesonide (Jorveza): (AVIR Pharma Inc.): Indication: For the Induction of Clinicopathologic Remission in Adults with Eosinophilic Esophagitis","year":"2020"},{"issue":"5","key":"10.1016\/j.xphs.2024.09.016_bib0019","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2020.07.039","article-title":"Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis","volume":"159","author":"Straumann","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.016_bib0020","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cgh.2020.03.060","article-title":"Improvements in dysphagia and pain with swallowing in patients with eosinophilic esophagitis receiving budesonide oral suspension","volume":"19","author":"Dellon","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.xphs.2024.09.016_bib0021","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.cgh.2021.06.020","article-title":"Long-term treatment of eosinophilic esophagitis with budesonide oral suspension","volume":"20","author":"Dellon","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.016_bib0022","first-page":"207","article-title":"Update on emerging pharmacologic therapies for patients with eosinophilic esophagitis","volume":"18","author":"Syverson","year":"2022","journal-title":"Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.016_bib0023","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/17425247.2022.2033206","article-title":"The challenges of drug delivery to the esophagus and how to overcome them","volume":"19","author":"Krause","year":"2022","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.016_bib0024","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2023.2219423","article-title":"Current status and advances in esophageal drug delivery technology: influence of physiological, pathophysiological and pharmaceutical factors","volume":"30","author":"Lim","year":"2023","journal-title":"Drug Deliv"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.016_bib0025","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.016_bib0026","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.addr.2004.08.009","article-title":"Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide","volume":"57","author":"Fedorak","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2024.09.016_bib0027","unstructured":"FDA Approves EOHILIA (budesonide oral suspension) | Takeda News. Accessed March 2, 2024. https:\/\/www.takeda.com\/newsroom\/newsreleases\/2024\/fda-approves-eohilia\/"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2024.09.016_bib0028","first-page":"13","article-title":"Nasal mucociliary clearance as a factor in nasal drug delivery","volume":"29","author":"Merkus","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"10.1016\/j.xphs.2024.09.016_bib0029","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3390\/pharmaceutics12090847","article-title":"Saponin micelles lead to high mucosal permeation and in vivo efficacy of solubilized budesonide","volume":"12","author":"Nakowitsch","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2024.09.016_bib0030","doi-asserted-by":"crossref","first-page":"340","DOI":"10.18433\/jpps32921","article-title":"Review of pharmaceutical applications of diethylene glycol monoethyl ether","volume":"25","author":"Hashemzadeh","year":"2022","journal-title":"J Pharm Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.016_bib0031","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1473-2165.2011.00590.x","article-title":"Diethylene glycol monoethyl ether: an emerging solvent in topical dermatology products: DEGEE: an emerging solvent","volume":"10","author":"Osborne","year":"2011","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.xphs.2024.09.016_bib0032","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jddst.2018.01.013","article-title":"Design and evaluation of SEDDS exhibiting high emulsifying properties","volume":"44","author":"Rohrer","year":"2018","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.xphs.2024.09.016_bib0033","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.fct.2014.06.028","article-title":"A review of the nonclinical safety of Transcutol\u00ae, a highly purified form of diethylene glycol monoethyl ether (DEGEE) used as a pharmaceutical excipient","volume":"72","author":"Sullivan","year":"2014","journal-title":"Food Chem Toxicol"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.016_bib0034","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/1567201811666140924124722","article-title":"Mucoadhesive polymeric platform for drug delivery; a comprehensive review","volume":"12","author":"Agarwal","year":"2015","journal-title":"Curr Drug Deliv"},{"issue":"9","key":"10.1016\/j.xphs.2024.09.016_bib0035","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1023\/A:1010631030320","article-title":"Architecture and function of the gastroesophageal barrier in the piglet","volume":"46","author":"Vicente","year":"2001","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.xphs.2024.09.016_bib0036","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1007\/s10620-006-9739-3","article-title":"Characterization of esophageal submucosal glands in pig tissue and cultures","volume":"52","author":"Abdulnour-Nakhoul","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"12","key":"10.1016\/j.xphs.2024.09.016_bib0037","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1002\/jps.20409","article-title":"Evaluation of pig esophageal mucosa as a permeability barrier model for buccal tissue","volume":"94","author":"Diaz Del","year":"2005","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.016_bib0038","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ijbiomac.2011.11.028","article-title":"Concentration selective hydration and phase states of hydroxyethyl cellulose (HEC) in aqueous solutions","volume":"50","author":"Arfin","year":"2012","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.xphs.2024.09.016_bib0039","unstructured":"European Commission. Directorate General for Health and Consumers. Opinion on Diethylene Glycol Monoethyl Ether (DEGEE). Publications Office; 2013. Accessed October 25, 2023. https:\/\/data.europa.eu\/doi\/10.2772\/36098"},{"key":"10.1016\/j.xphs.2024.09.016_bib0040","series-title":"Industrial Gums","first-page":"505","article-title":"Hydroxyalkyl and ethyl ethers of cellulose","author":"Desmarais","year":"1993"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.016_bib0041","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/jfb12020028","article-title":"Rheological behavior of a new mucoadhesive oral formulation based on sodium chondroitin sulfate, xyloglucan and glycerol","volume":"12","author":"Pecora","year":"2021","journal-title":"J Funct Biomater"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.016_bib0042","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/pharmaceutics12030211","article-title":"Mucoadhesive budesonide formulation for the treatment of eosinophilic esophagitis","volume":"12","author":"Casiraghi","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2024.09.016_bib0043","series-title":"Essential Chemistry for Formulators of Semisolid and Liquid Dosages","first-page":"43","article-title":"Use of polymers and thickeners in semisolid and liquid formulations","author":"Kulkarni","year":"2016"},{"issue":"11","key":"10.1016\/j.xphs.2024.09.016_bib0044","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.addr.2005.07.001","article-title":"The basics and underlying mechanisms of mucoadhesion","volume":"57","author":"Smart","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2024.09.016_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114445","article-title":"Using thermal forced degradation approach for impurity profiling of budesonide solution-formulated metered dose inhalation with implementation of LC-QTOFMS and HPLC-UV","volume":"208","author":"Peng","year":"2022","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"10.1016\/j.xphs.2024.09.016_bib0046","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2460\/ajvr.74.6.895","article-title":"Evaluation of esophageal high-resolution manometry in awake and sedated dogs","volume":"74","author":"Kempf","year":"2013","journal-title":"Am J Vet Res"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.016_bib0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1117\/1.JBO.23.4.046004","article-title":"Feasibility of using optical coherence tomography to detect acute radiation-induced esophageal damage in small animal models","volume":"23","author":"Jelvehgaran","year":"2018","journal-title":"J Biomed Opt"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.016_bib0048","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13014-019-1396-8","article-title":"Evaluation of acute esophageal radiation-induced damage using magnetic resonance imaging: a feasibility study in mice","volume":"14","author":"Jelvehgaran","year":"2019","journal-title":"Radiat Oncol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924004234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924004234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:53Z","timestamp":1777420853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924004234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0022354924004234"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.09.016","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral viscous budesonide solution for enhanced localized treatment of eosinophilic esophagitis through improved mucoadhesion and permeation","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}